Why did 2289.HK stock drop pre-market today?

The pre-market drop for 2289.HK stock to HKD 5.60 (-23.08%) reflected heavy selling and higher-than-average volume. Immediate drivers were concerns about dividend sustainability, weak interest coverage (0.74x) and elevated debt-to-equity (1.78).

What is Meyka AI’s price forecast for 2289.HK stock?

Meyka AI's model projects a monthly target of HKD 6.12 (+9.29%), a quarterly level of HKD 5.01 (-10.68%), and a yearly projection of HKD 3.25 (-41.92%). These are model-based projections and not guarantees.

Is 2289.HK stock a value buy after the fall?

Valuation looks inexpensive on PE 11.15 versus sector averages, but payout ratio above 100% and stretched receivables increase risk. Meyka AI gives a B (HOLD) grade, suggesting caution until cash flow and dividend clarity improve.

What operational metrics should investors monitor for 2289.HK stock?

Focus on cash conversion cycle, days sales outstanding (~106.95 days), operating cash flow per share (HKD 2.60), and any changes to dividend policy. Improvements here would reduce downside risk.

HK Stocks

2289.HK stock down 23.08% pre-market 29 Jan 2026: key drivers to watch

ByDanny Kontos January 29, 2026

The 2289.HK stock of Charmacy Pharmaceutical (HKSE) plunged 23.08% in pre-market trading on 29 Jan 2026, weighing the Hong Kong healthcare small cap. Shares opened at HKD 5.95 and last traded at HKD 5.60, with intraday extremes at HKD 4.30–5.95 and a volume spike of 42,000 shares vs average 262. The drop follows heavier-than-normal selling and highlights valuation, dividend sustainability and sector comparisons as immediate investor concerns for this China-focused medical-distribution company.